New Paradigm for the Treatment of Thyroid Eye Disease (Slides)

Update item information
Identifier 20200312_nanos_newtreatmentsno1_01-slides
Title New Paradigm for the Treatment of Thyroid Eye Disease (Slides)
Creator Prem Subramanian, MD, PhD
Subject Graves Disease; Intravenous Corticosteroid; Teprotumumab; Clinical Activity Scale Score
Description Thyroid-related ophthalmopathy (TRO) or thyroid eye disease (TED) occurs in up to 50% of patients with systemic Graves hyperthyroidism as well as a smaller percentage of patients with other autoimmune thyroid disorders such as Hashimoto thyroiditis. Some of the underlying immunological mechanisms have been studied and elucidated, including stimulatory pathways that lead to orbital fibroblast proliferation, fat hypertrophy, and extraocular muscle changes.
Relation is Part of NANOS Annual Meeting 2020: New Treatments in Neuro-Ophthalmology - 2020 Trends
Contributor Primary Prem Subramanian, MD, PhD
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date 2020-03
Format application/pdf
Source 2020 North American Neuro-Ophthalmology Society Annual Meeting
Rights Management Copyright 2020. For further information regarding the rights to this collection, please visit:
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Collection Neuro-ophthalmology Virtual Education Library: NOVEL
Language eng
ARK ark:/87278/s6n355t5
Setname ehsl_novel_nam
Date Created 2020-04-16
Date Modified 2020-05-27
ID 1541463
Reference URL
Back to Search Results